Pericarditis Drugs Market Introduction

Pericarditis is the inflammation of the pericardium. Pericardium is two thin layers of a sac like structure of tissues that surrounds the heart. The pericardium holds the heart in place and helps it work. It is a small amount of fluid that keeps both the layers separated from each other so that there is no friction between the layers. Pericarditis often causes chest pain and other symptoms too. The harsh chest pain associated with pericardium occurs when the layers of the pericardium rub against each other. Pericarditis usually begins suddenly but does not last for long.

When symptoms related to pericarditis develops more gradually or persists, it is considered as chronic pericarditis. Most cases of pericarditis are mild and usually improve on their own. The common symptoms related to pericarditis include cough; leg or abdominal swelling; low-grade fever; heart palpitations; shortness of breath when reclining; an overall sense of weakness, feeling sick or fatigue; and sharp, piercing chest pain. Pericarditis can be diagnosed with the help of electrocardiogram results, echocardiogram, physical examination, cardiac MRI, and reported symptoms.

Pericarditis Drugs Market – Competitive Landscape

Hoffmann-La Roche AG

Founded in 1896, F. Hoffmann-La Roche AG is headquartered in Basel, Switzerland. It is a global biopharmaceutical company engaged in the development, manufacture, and commercialization of pharmaceutical products and medical devices. Roche Pharmaceuticals is a world leader in biotechnology and oncology.

Identify the key factors that will drive your company’s growth, Request a brochure of this report here

Bayer AG

Incorporated in 1863, Bayer AG is based in Leverkusen, Germany. It is a chemical and pharmaceutical company that markets products, helping prevent, diagnose, and treat diseases for humans and animals. The pharmaceutical division emphasizes on prescription products and specialty therapeutics in the areas of cardiology, women’s health, hematology, oncology, and ophthalmology.

Pfizer Inc.

Established in 1849, Pfizer Inc. is based in New York, U.S. It is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments including cardiovascular, oncology, neuroscience, pain, infectious diseases, etc. The company offers a wide range of medicines and vaccines as well as consumer health care products for the prevention and treatment of infectious and chronic diseases for all age groups.

AstraZeneca plc

AstraZeneca was formed in 1999 through the merger of Sweden-based Astra AB and the U.K.-based Zeneca Group. AstraZeneca is a pharmaceutical company engaged in the discovery, manufacture, distribution, and commercialization of pharmaceutical products. The company is engaged in a single business activity of biopharmaceuticals through which it offers solutions for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Pericarditis Drugs Market Dynamics

Rise in Prevalence of Pericarditis and Cardiovascular Diseases Driving Demand for Pericarditis Drugs

Increase in prevalence of cardiovascular diseases and pericarditis expected to drive the demand for pericarditis drugs. According to Cureus, an open access medical journal for a new generation of doctors and patients, acute pericarditis is the most common disease in several clinical settings. The incidence of acute pericarditis is recorded between 0.1% to 0.2% of hospitalized patients, and 5% of the patients admitted to the emergency department with non-ischemic chest pain. Furthermore, 17.9 million people die worldwide each year from cardiovascular diseases, an estimated 31% of all deaths worldwide. About more than 75% of cardiovascular deaths occur in low and middle income countries.

Expanding operations in future? To get the perfect launch ask for a custom report here

Key players in the market are focusing on the development of novel and effective drugs for pericarditis treatment

A key factor propelling the growth of the global pericarditis drugs market is the adoption of dual therapy for the treatment of idiopathic pericarditis. Conventionally, aspirin as monotherapy is used to treat acute pericarditis. However, clinical trials are being carried out for dual therapy with the combination of two drug aspirin with colchicine for the treatment of pericarditis. The results have shown that combination therapy is effective in reducing the recurrence rate of pericarditis as compared to conventional monotherapy.

Therefore, use of dual therapy such as aspirin with colchicine is anticipated to increase with rise in prevalence of idiopathic pericarditis with repeated episodes. However, few side effects of anti-inflammatory drugs, presence of misbranded drugs, surgical intervention, and stringent government rules are expected to hinder the growth of the global pericarditis drugs market during the forecast period.

Pericarditis Drugs Market – Segmentation

The pericarditis drugs market can be bifurcated on the basis of:

  • Drug Type
  • Distribution Channel
  • Region

Pericarditis Drugs Market Segmentation – By Drug Type

Depending on the drug type, the pericarditis drugs market can be divided into:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Colchicine
  • Others

Pericarditis Drugs Market Segmentation – By Distribution Channel

On the basis of the distribution channel, the pericarditis drugs market can be fragmented into:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

The report on pericarditis drugs market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The pericarditis drugs market report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The pericarditis drugs market report also maps the qualitative impact of various market factors on pericarditis drugs market segments and geographies

Regional analysis for pericarditis drugs market includes:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Pericarditis Drugs Market

Pre Book